slides · global inventory
27 Cost Of Inaction
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 31,900
Current window 20,851-20,880
Pages 1,064
Rows per page 30
Loop
20,851-20,880 of 31,900
07
Includes branding imagery with Naomi Campbell.Hugo Boss | Results Presentation Deck | 22 slides · Hugo Boss
Conference presentation Investor relations Beat · Rising SuccessLoop · Cost Of Inaction1 hit
08
The chart highlights the company's 'Claim 5' strategy success.Hugo Boss | Results Presentation Deck | 22 slides · Hugo Boss
Conference presentation Investor relations Beat · Rising SuccessLoop · Cost Of Inaction1 hit
09
The slide uses brand-specific color coding (brown for BOSS, red for HUGO) and includes lifestyle photography.Hugo Boss | Results Presentation Deck | 22 slides · Hugo Boss
Conference presentation Investor relations Beat · Rising SuccessLoop · Cost Of Inaction1 hit
10
The slide uses a three-column layout to highlight growth metrics for different business segments.Hugo Boss | Results Presentation Deck | 22 slides · Hugo Boss
Conference presentation Investor relations Beat · Rising SuccessLoop · Cost Of Inaction1 hit
11
The slide highlights the brand's focus on physical retail transformation.Hugo Boss | Results Presentation Deck | 22 slides · Hugo Boss
Conference presentation Investor relations Beat · Rising SuccessLoop · Cost Of Inaction1 hit
12
Currency-adjusted figures.Hugo Boss | Results Presentation Deck | 22 slides · Hugo Boss
Conference presentation Investor relations Beat · Rising SuccessLoop · Cost Of Inaction1 hit
13
The chart uses a bridge format to explain the 120 basis point decline against a 110 basis point positive contribution from other factors.Hugo Boss | Results Presentation Deck | 22 slides · Hugo Boss
Conference presentation Investor relations Beat · Rising SuccessLoop · Cost Of Inaction1 hit
14
The slide uses a table format to present key financial KPIs for Hugo Boss.Hugo Boss | Results Presentation Deck | 22 slides · Hugo Boss
Conference presentation Investor relations Beat · Rising SuccessLoop · Cost Of Inaction1 hit
03
The slide uses a circular central graphic to anchor the list of pain points.Hyperfine | Investor Presentation Deck | 16 slides · Hyperfine
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
Hyperfine | Investor Presentation Deck | 16 slidesHyperfine | Investor Presentation Deck | 16 slides · Hyperfine
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
04
The slide uses a wave-like visual to represent market segments and their associated financial opportunities.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
05
The table uses a standard pharmaceutical pipeline format, categorizing by clinical vs preclinical status and therapy type (CAR-T vs TSTx).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
The slide uses a grouped bar chart to compare clinical outcomes across different patient segments (No BCMA, Yes BCMA, Overall).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
07
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
08
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
09
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
07
The slide uses a hub-and-spoke diagram to illustrate the negative consequences of neurotoxicity.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
08
Includes a cartoon liver character, likely representing the target organ or safety profile.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
09
Includes extensive disclaimer text regarding cross-trial comparison limitations.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
10
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
11
Includes detailed source citations in the footer; uses a color-coded legend for different drug treatments.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
12
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
13
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
14
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
15
The slide uses a table structure to contrast clinical outcomes across three key value pillars: response rates, tolerability, and outpatient feasibility.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
16
Includes comparative data points for transduction efficiency and experimental data for tonic signaling and anti-exhaustion.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
17
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs. competitors.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
18
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
09
The slide uses a hub-and-spoke diagram to illustrate the central problem of CAR-T neurotoxicity and its four primary negative outcomes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Includes a cartoon liver character at the bottom.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit